BEST OF ONCOLOGY WEST 2024: Breast Cancer – Dr. Nancy Nixon
OR
Chair
Dr. Sharlene Gill
Dr. Daniel Heng
Panelist
Dr. Nancy Nixon
Studies/trials discussed:
- Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
- Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2early breast cancer: Primary results from the phase III NATALEE trial.
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- Keynote 522Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
- KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.
- A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2primary breast cancer: CheckMate 7FL.
- Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
- 389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2metastatic breast cancer (mBC)
- DestinyBreast 04 Study Design
- TropionB01 Study
